Business Wire

The DVLA and Thales Cut Carbon Footprint of UK Driving Licence and Residence Cards

Share

The United Kingdom government’s Driver and Vehicle Licensing Agency (DVLA) partners with Thales to reduce the carbon footprint of its driving licences as well as tachograph and residence cards. Since 2018, Thales has cut by over one third the CO2 emissions associated with the 12 million cards it supplies to the DVLA every year, without compromising the outstanding security, durability and value-for-money provided by these products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604196678/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(credit: Shutterstock – Jubemo/Thales)

The DVLA is responsible for maintaining accurate records of more than 52 million drivers in Great Britain and more than 46 million vehicles across the UK. It is also recognised as a centre of excellence for sourcing and issuing secure national documents. Since 2012, Thales has supplied the DVLA with polycarbonate driving licences, a range of tachograph cards (for operations such as recording and storing the activity of commercial drivers), and residence cards for EU citizens to prove their right to live and work in the UK.

Key initiatives undertaken by Thales include adoption of eco-design principles throughout its identity card portfolio. For example, the size of the contactless microcontrollers embedded in the UK’s tachograph and residence cards has been halved, resulting in an equivalent reduction in CO2 microcontroller emissions while maintaining applications and security features unchanged.

In addition, Thales’ factories manufacturing the cards are accredited to the ISO 50001 standard, which focuses on energy efficiency. All these factories use 100% renewably electricity, accounting for over 70% of their total energy consumption. These improvements resulted in a reduction of over 80% of manufacturing related emissions (scope 1 and 2) since 2018.

For the remaining emissions of DVLA cards and on a yearly basis, Thales invests in high quality carbon offsetting programs with independently recognized carbon compensation organization such as Climate Impact Partners. For the DVLA contract, these include planting forests in the UK, restoring mangroves in Kenya, and distributing clean energy stoves in Bangladesh. In total, Thales has now offset 3,000 tonnes of CO2 emissions on behalf of the DVLA.

“Just like the DVLA, Thales is on the road to net zero and uses industry standard tools to calculate the Life Cycle Assessments of its products. This comprehensive calculator1 assesses the environmental impact of materials, packaging, transportation, document production and distribution, as well as end of life. Together with DVLA we are continually exploring new opportunities to improve the sustainability of the millions of cards supplied by Thales, looking for more responsible materials and solutions. At the same time, we remain focused on the need to maintain the security and integrity of identity credentials and deliver exceptional value for money for governments and public bodies” saidNathalie Gosset, Vice President Identity Document Solutions at Thales

1 This approach was developed with Quantis, a leading environmental sustainability consultancy, and is now supported by Solinnen, an expert consultancy specialising in Life Cycle Assessment, following recognised standards which consider the full life cycle of the products assessed and covers associated scope 1, 2 and 3.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.

It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.

Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

PLEASE VISIT

Thales Group
Digital Identity & Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT

Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release

Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release

ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye